Expansion from CHECKMATE-032; nivolumab and ipilimumab for metastatic urothelial carcinoma

Bookmark and Share
Published: 21 Oct 2018
Views: 1465
Dr Jonathan E. Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA

Dr Jonathan E. Rosenberg talks to ecancer at ESMO 2018 about the CHECKMATE-032 trial looking at nivolumab with ipilimumab for patients with metastatic urothelial carcinoma.

After giving the latest data from the study, Dr Rosenberg provides his opinions and also the future direction for patients with metastatic urothelial carcinoma, given these outcomes.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.